Sangamo BioSciences (SGMO)
Sangamo BioSciences Revenues: 3.242M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SGMO Revenues Rankings
| Overall | 5th percentile | 4207 of 4431 |
| Sector | 20th percentile | 376 of 471 in Healthcare |
| Industry | 34th percentile | 86 of 132 in Biotechnology |
SGMO Revenues Range, Past 5 Years
| Minimum | 1.514M | Jun 2011 |
| Maximum | 10.24M | Dec 2009 |
| Average | 4.021M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these SGMO related companies
SGMO News
Sangamo BioSciences' CEO Presents at Bank of America Merrill Lynch 2012 Health Care Conference (Transcript)
May 16, 8:07PM Seeking Alpha
May 16, 8:07PM Seeking Alpha
Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
May 07, 4:15PM PR Newswire
May 07, 4:15PM PR Newswire
Listen to $SGMO Q1 2012 earnings call - live at 05:00 PM, ondemand after - http://stks.co/3dRG
about 30 days ago by earningscast
about 30 days ago by earningscast
Sangamo BioSciences Nominates Saira Ramasastry To The Company's Board Of Directors
Apr 30, 7:00AM PR Newswire
Apr 30, 7:00AM PR Newswire
Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
Apr 25, 4:00PM PR Newswire
Apr 25, 4:00PM PR Newswire
heres a company $sgmo with cure for aides at 4.50 a share do you know how many africans have aides the stock should be 10.00 by now ?
about 43 days ago by justkyle
about 43 days ago by justkyle
Sangamo BioSciences Announces Presentation at the Future Leaders in the Biotech Industry Conference
Apr 12, 5:30PM PR Newswire
Apr 12, 5:30PM PR Newswire
$SGMO BOASTING AND NOW BACKED UP BY SOME REASERCHERS OF AIDES CURE STILL AT AMAZING PRICE OF LESS THEN 5 DOLLARS
about 50 days ago by justkyle
about 50 days ago by justkyle
$SGMO this is a cinderella stock ive seen sgmo at 19 dollars with far less then a fundemental cure for aides if it goes its gonna happen
about 54 days ago by justkyle
about 54 days ago by justkyle
Sangamo BioSciences (SGMO) Reports Publication of Preclinical ZFN Data
Apr 02, 7:27AM Street Insider
Apr 02, 7:27AM Street Insider
Sangamo BioSciences Announces Presentation at Needham Healthcare Conference
Mar 28, 4:00PM PR Newswire
Mar 28, 4:00PM PR Newswire
$SGMO http://stks.co/36x7 reverse H&S here, can resolve into a breakout higher - $SGMO #BIOTECHS
about 66 days ago by LTbioinvestor
about 66 days ago by LTbioinvestor
$SGMO Presents New Clinical Data at CROI 2012 Demonstrating Persistent Positive Effects of ZFN Therapeutic for "Functional Cure" of HIV/AIDS
about 85 days ago by Benzinga
about 85 days ago by Benzinga
ok latest update on $sgmo they recieved 13 million plus royalty and black rock aquired 6% for who knows how much
about 96 days ago by justkyle
about 96 days ago by justkyle
$SGMO http://stks.co/2Tlz small bio name, with some chatter around lately. Nice chart. $SGMO
about 102 days ago by LTbioinvestor
about 102 days ago by LTbioinvestor
$sgmo up 27% the stock is a steal with fundemental cure for aides on the horison
about 105 days ago by justkyle
about 105 days ago by justkyle
Quant modell indicates a 5 - 1 chance for $SGMO not closing above 5.08 today. Now trading at 5.02 or +19.5%
about 105 days ago by TradeBot
about 105 days ago by TradeBot
$SGMO Upside Blowoff - 15 Minute Down Reversal - Red bar after 7 higher highs and higher lows
about 105 days ago by TradeIdeasQuant
about 105 days ago by TradeIdeasQuant
$SGMO Upside Blowoff - 15 Minute Down Reversal - Red bar after 4 higher highs and higher lows
about 105 days ago by TradeIdeasQuant
about 105 days ago by TradeIdeasQuant
Sangamo BioSciences Announces Presentation at 2012 Leerink Swann Global Healthcare Conference
Feb 09, 4:00PM PR Newswire
Feb 09, 4:00PM PR Newswire
$SGMO 200 Day SMA Cross - Price crossed below 200 day SMA (4.6047). Confirmed by volume.
about 113 days ago by TradeIdeasQuant
about 113 days ago by TradeIdeasQuant
Sangamo BioSciences' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Feb 08, 10:20PM Seeking Alpha
Feb 08, 10:20PM Seeking Alpha
Listen to $SGMO Q4 2011 earnings call (EPS -0.12 vs est -0.12) - live at 05:00 PM, ondemand after - http://stks.co/2JZb
about 114 days ago by earningscast
about 114 days ago by earningscast
Sangamo BioSciences Reports Fourth Quarter and Full Year 2011 Financial Results
Feb 08, 4:00PM PR Newswire
Feb 08, 4:00PM PR Newswire
Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
Feb 01, 4:05PM PR Newswire
Feb 01, 4:05PM PR Newswire
Sangamo BioSciences' CEO Presents at the 30th Annual J.P. Morgan Healthcare Conference (Transcript)
Jan 12, 3:19PM Seeking Alpha
Jan 12, 3:19PM Seeking Alpha
Sangamo BioSciences Announces Initiation of Two New Phase 2 HIV Clinical Trials
Jan 09, 7:02AM Benzinga
Jan 09, 7:02AM Benzinga
Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
Jan 05, 4:00PM PR Newswire
Jan 05, 4:00PM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SGMO | 4.23 | -0.21 | -4.73% | 233.37M |
| SGMA | 3.77 | -0.03 | -0.79% | 14.86M |
| SGK | 10.66 | -0.49 | -4.39% | 287.22M |
| SGI | 5.55 | -0.34 | -5.77% | 186.36M |
| SGGG | 58.88 | -0.97 | -1.62% | |
| VE | 11.20 | -0.26 | -2.23% | 5.792B |
| VDSI | 6.85 | -0.14 | -2.00% | 267.37M |
| VDE | 90.26 | -2.27 | -2.45% | |
| VCO | 35.12 | -1.08 | -2.98% | 1.352B |
| VCLK | 16.80 | -0.74 | -4.22% | 1.409B |